Oncopeptides AB (FRA:OND) ROC (Joel Greenblatt) %: -908.47% (As of Mar. 2026)


FRA:OND Oncopeptides AB FRA:OND
26 GF Score
Price €0.14
GF Value €0.39
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB ROC (Joel Greenblatt) %?

Oncopeptides AB FRA:OND -0.57% 26 ROC (Joel Greenblatt) % is -908.47% as of Mar. 2026. GuruFocus rates FRA:OND with a GF Score™ of 26/100 and a GF Value™ of €0.39 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,320 Biotechnology companies, Oncopeptides AB ranks worse than 67.12% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Oncopeptides AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -908.47%.

The historical rank and industry rank for Oncopeptides AB's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:OND' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -20676.78   Med: -3744.94   Max: -879.7
Current: -1008.76

During the past 12 years, Oncopeptides AB's highest ROC (Joel Greenblatt) % was -879.70%. The lowest was -20676.78%. And the median was -3744.94%.

FRA:OND's ROC (Joel Greenblatt) % is ranked worse than
67.12% of 1320 companies
in the Biotechnology industry
Industry Median: -294.23 vs FRA:OND: -1008.76

Oncopeptides AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 32.90% per year.


Oncopeptides AB  (FRA:OND) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Oncopeptides AB ROC (Joel Greenblatt) % Related Terms


Oncopeptides AB ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB ROC (Joel Greenblatt) % Chart

Oncopeptides AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,478.56 -1,435.61 -875.78 -866.03 -1,078.70

Oncopeptides AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -945.39 -951.28 -891.27 -1,316.80 -908.47

FRA:OND vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Oncopeptides AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's ROC (Joel Greenblatt) % falls into.


FRA:OND
26GF Score
Oncopeptides AB FRA:OND
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncopeptides AB ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.714 + 0.758 + 1.373) - (0.453 + 0 + 2.978)
=-0.586

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.864 + 0.888 + 0.0010000000000012) - (1.221 + 0 + 4.006)
=-0.474

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Oncopeptides AB for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-13.936/( ( (1.625 + max(-0.586, 0)) + (1.443 + max(-0.474, 0)) )/ 2 )
=-13.936/( ( 1.625 + 1.443 )/ 2 )
=-13.936/1.534
=-908.47 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -908.47% mean?
Oncopeptides AB (FRA:OND) has a ROC (Joel Greenblatt) % of -908.47% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #886 out of 1320 companies in the Biotechnology industry, placing it in the top 67.1%.
Is Oncopeptides AB's ROC (Joel Greenblatt) % too high?
Oncopeptides AB's current ROC (Joel Greenblatt) % is -908.47%. Based on the distribution chart, Oncopeptides AB ranks #886 out of 1320 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncopeptides AB has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #886 out of 1320 companies for ROC (Joel Greenblatt) %. This places Oncopeptides AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current ROC (Joel Greenblatt) % is -908.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.39, compared to a current price of €0.14 — trading 64.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is -908.47%. Oncopeptides AB's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current ROC (Joel Greenblatt) % is -908.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (FRA:OND) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of €0.14 is trading 64.2% below its estimated GF Value™ of €0.39. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for FRA:OND:

  • ROC (Joel Greenblatt) %: -908.47%
  • GF Value™: €0.39 vs. price of €0.14 (64.2% below fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncopeptides AB Business Description

Other Exchanges ONCO:SwedenONCOs:UK0RN4:UK
Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
26GF Score

Get the complete analysis for FRA:OND

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.39
GF Value